[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsed-or-refractory-autoimmune-cytopenias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsed-or-refractory-autoimmune-cytopenias":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100651745","phase-1-phase-1-dose-escalation-study-of-rxim002-in-autoimmune-cytopenias-100651745",false,"NCT07765966","Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias","A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Early Efficacy of RXIM002, in Patients With Relapsed or Refractory Autoimmune Cytopenias","POPULUS-1","Inclusion Criteria:\n\n* 18-75 years of age\n* Diagnosed with primary ITP\n* Relapsed or refractory ITP\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to messenger ribonucleic acid (mRNA) vaccines or other RNA-LNP products\n* Any active infection\n* Heart failure, reduced kidney function, or liver abnormalities","ALL","18 Years","75 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.",[28,29],"Relapsed or Refractory Autoimmune Cytopenias","Immune Thrombocytopenia (ITP)",[31,29,32,33,34,35],"Relapsed or refractory autoimmune cytopenias","Circular ribonucleic acid","Chimeric Antigen Receptor (CAR)","Anti-human CD19","in vivo CAR-T therapy","NOT_YET_RECRUITING","2026-08-10",{"date":39,"type":40},"2026-08-14","ACTUAL",{"date":42,"type":22},"2027-02-01",{"date":44,"type":22},"2029-12-31",{"name":46,"class":47},"RiboX Therapeutics Ltd.","INDUSTRY"]